Mainstay Medical Holdings plc has announced an equity financing in which it will receive gross proceeds of US$125 million. Mainstay intends to use the funds to support the company’s continued commercial growth of ReActiv8® Restorative Neurostimulation in the US, Europe, and Australia, additional post-market clinical studies and research, and general operations. Latham & Watkins LLP advised Mainstay Medical Holdings in the transaction with a corporate team led by San Diego partners Cheston Larson and Matt Bush, and counsel Evan Youngstrom, with associate Alex Stuart-Lovell.~~